NEO logo

NEO
Neogenomics Inc.

2,871
Mkt Cap
$1.07B
Volume
1.11M
52W High
$13.74
52W Low
$4.72
PE Ratio
-10.66
NEO Fundamentals
Price
$8.24
Prev Close
$8.36
Open
$8.39
50D MA
$8.30
Beta
1.36
Avg. Volume
2.67M
EPS (Annual)
-$0.8433
P/B
1.29
Rev/Employee
$290,932.80
$1,756.31
Loading...
Loading...
News
all
press releases
NeoGenomics to Participate in Upcoming Investor Conferences
NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of oncology diagnostic solutions that enable precision medicine, today announced the Company will participate in the following investor conferences...
Business Wire·1d ago
News Placeholder
More News
News Placeholder
TD Cowen Issues Positive Forecast for NeoGenomics (NASDAQ:NEO) Stock Price
TD Cowen boosted their target price on shares of NeoGenomics from $13.00 to $14.00 and gave the company a "buy" rating in a research note on Wednesday...
MarketBeat·17d ago
News Placeholder
NeoGenomics (NASDAQ:NEO) Shares Gap Up Following Analyst Upgrade
NeoGenomics (NASDAQ:NEO) Shares Gap Up on Analyst Upgrade...
MarketBeat·17d ago
News Placeholder
Wall Street’s Next Biotech Winners Emerge as FDA Acceleration Unleashes New Markets
The biotech and health-tech landscape is entering a new acceleration phase, driven by regulatory momentum, AI integration, and a surge in precision medicine. $NEO, $TGNT, $XTLB, $SAGT, $PRCH, $AKAN
24-7 Market News·17d ago
News Placeholder
NeoGenomics (NASDAQ:NEO) Upgraded by Leerink Partners to Outperform Rating
Leerink Partners upgraded NeoGenomics from a "market perform" rating to an "outperform" rating and increased their target price for the company from $12.00 to $25.00 in a research report on Wednesday...
MarketBeat·17d ago
News Placeholder
NeoGenomics (NASDAQ:NEO) Announces Quarterly Earnings Results, Hits Estimates
NeoGenomics (NASDAQ:NEO - Get Free Report) released its earnings results on Tuesday. The medical research company reported $0.01 earnings per share for the quarter, meeting analysts' consensus...
MarketBeat·18d ago
News Placeholder
NeoGenomics Q1 Earnings Call Highlights
NeoGenomics (NASDAQ:NEO) reported first-quarter 2026 results that management said reflected continued momentum in its clinical business and growing contributions from newer, higher-value oncology...
MarketBeat·18d ago
News Placeholder
NeoGenomics (NEO) Q1 2026 Earnings Transcript
@media (max-width: 768px) { .image-container { width: 100% !important; float: none !important; margin: 0 0 1rem 0 !important; } } Image source: The Mo...
Nasdaq News: Markets·18d ago
News Placeholder
NeoGenomics (NEO) Q1 2025 Earnings Transcript
@media (max-width: 768px) { .image-container { width: 100% !important; float: none !important; margin: 0 0 1rem 0 !important; } } Image source: The Mo...
Nasdaq News: Markets·18d ago
News Placeholder
NeoGenomics Reports First Quarter 2026 Results
NeoGenomics, Inc. (NASDAQ: NEO) (the Company), a leading provider of oncology diagnostic solutions that enable precision medicine, today announced its first quarter results for the period ended March...
Business Wire·18d ago
<
1
2
...
>

Latest NEO News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.